- Home
- MGIH vs MEIP Comparison
MGIH vs MEIP Comparison
Compare MGIH & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- MEIP
- Stock Information
- Founded
- MGIH 1978
- MEIP 2000
- Country
- MGIH Hong Kong
- MEIP United States
- Employees
- MGIH N/A
- MEIP N/A
- Industry
- MGIH Publishing
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- MEIP Health Care
- Exchange
- MGIH Nasdaq
- MEIP Nasdaq
- Market Cap
- MGIH 20.5M
- MEIP 18.5M
- IPO Year
- MGIH 2023
- MEIP 2003
- Fundamental
- Price
- MGIH $1.67
- MEIP $2.60
- Analyst Decision
- MGIH
- MEIP Hold
- Analyst Count
- MGIH 0
- MEIP 2
- Target Price
- MGIH N/A
- MEIP $7.00
- AVG Volume (30 Days)
- MGIH 55.0K
- MEIP 7.5K
- Earning Date
- MGIH 10-30-2024
- MEIP 02-12-2025
- Dividend Yield
- MGIH N/A
- MEIP N/A
- EPS Growth
- MGIH N/A
- MEIP N/A
- EPS
- MGIH N/A
- MEIP N/A
- Revenue
- MGIH $38,530,773.00
- MEIP N/A
- Revenue This Year
- MGIH N/A
- MEIP N/A
- Revenue Next Year
- MGIH N/A
- MEIP N/A
- P/E Ratio
- MGIH N/A
- MEIP N/A
- Revenue Growth
- MGIH N/A
- MEIP 33.76
- 52 Week Low
- MGIH $1.19
- MEIP $2.30
- 52 Week High
- MGIH $6.83
- MEIP $4.42
- Technical
- Relative Strength Index (RSI)
- MGIH 50.94
- MEIP 37.79
- Support Level
- MGIH $1.47
- MEIP $2.55
- Resistance Level
- MGIH $1.64
- MEIP $2.79
- Average True Range (ATR)
- MGIH 0.21
- MEIP 0.14
- MACD
- MGIH -0.01
- MEIP -0.02
- Stochastic Oscillator
- MGIH 29.85
- MEIP 14.71
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.